PMID- 20414943
OWN - NLM
STAT- MEDLINE
DCOM- 20100513
LR  - 20191210
IS  - 1107-0625 (Print)
IS  - 1107-0625 (Linking)
VI  - 15
IP  - 1
DP  - 2010 Jan-Mar
TI  - Contribution of (99m)Tc-depreotide (Neospect) scintigraphy in lung cancer 
      staging.
PG  - 147-52
AB  - PURPOSE: The aim of this study was to evaluate the usefulness of scintigraphy 
      with (99m)Tc-depreotide in the staging of lung cancer, especially in cases where 
      CT findings are doubtful. METHODS: 53 patients with suspected lung cancer were 
      investigated with whole body planar acquisition and single photon emission 
      computed tomography (SPECT) of the thorax after i.v. injection of 740 MBq 
      (99m)Tc-depreotide (Neospect). The results were compared with CT and correlated 
      with histological findings. RESULTS: In 50 of 53 patients the biopsy was positive 
      for bronchogenic carcinoma (31 patients with non small cell lung cancer [NSCLC], 
      18 with small cell lung cancer (SCLC), and 1 patient with neuroendocrine cancer). 
      In the remaining 3, biopsy revealed no bronchogenic carcinoma (3 patients with 
      inflammation). In 2/31 patients with NSCLC and doubtful CT findings, uptake of 
      (99m)Tc-depreotide was the only non invasive reliable staging method. CONCLUSION: 
      It seems that scintigraphy with (99m)Tc-depreotide in patients with SCLC does not 
      change the tumor stage, whereas in NSCLC the contribution of Neospect in lung 
      cancer staging may be a helpful tool, especially in cases where CT alone is 
      unable to distinguish between IIIA and IIIB stages (operable from non operable 
      status).
FAU - Karathanos, E
AU  - Karathanos E
AD  - Department of Nuclear Medicine, University General Hospital of Alexandroupolis, 
      Dragana, Alexandroupolis, Greece. karathanos@yahoo.com
FAU - Datseris, I
AU  - Datseris I
FAU - Vlontzou, E
AU  - Vlontzou E
FAU - Zisimopoulos, A
AU  - Zisimopoulos A
FAU - Georgiou, E
AU  - Georgiou E
LA  - eng
PT  - Comparative Study
PT  - Evaluation Study
PT  - Journal Article
PL  - Cyprus
TA  - J BUON
JT  - Journal of B.U.ON. : official journal of the Balkan Union of Oncology
JID - 100883428
RN  - 0 (Organotechnetium Compounds)
RN  - 0 (Radiopharmaceuticals)
RN  - 51110-01-1 (Somatostatin)
RN  - 9M48M2SF02 (technetium Tc 99m depreotide)
SB  - IM
MH  - Aged
MH  - Biopsy
MH  - Carcinoma, Non-Small-Cell Lung/*diagnostic imaging/pathology
MH  - Female
MH  - Humans
MH  - Injections, Intravenous
MH  - Lung Neoplasms/*diagnostic imaging/pathology
MH  - Male
MH  - Middle Aged
MH  - Neoplasm Staging
MH  - Neuroendocrine Tumors/*diagnostic imaging/pathology
MH  - *Organotechnetium Compounds/administration & dosage
MH  - Predictive Value of Tests
MH  - *Radiopharmaceuticals/administration & dosage
MH  - Reproducibility of Results
MH  - Small Cell Lung Carcinoma/*diagnostic imaging/pathology
MH  - Somatostatin/administration & dosage/*analogs & derivatives
MH  - *Tomography, Emission-Computed, Single-Photon
MH  - Tomography, X-Ray Computed
EDAT- 2010/04/24 06:00
MHDA- 2010/05/14 06:00
CRDT- 2010/04/24 06:00
PHST- 2010/04/24 06:00 [entrez]
PHST- 2010/04/24 06:00 [pubmed]
PHST- 2010/05/14 06:00 [medline]
PST - ppublish
SO  - J BUON. 2010 Jan-Mar;15(1):147-52.